Astatine-211 Growth Drivers & Forecast Analysis 2033

Astatine-211 by Application (Scientific Research, Cancer Therapy), by Types (Produced by Bombardment of Bismuth, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $5.9 million

CAGR: 37.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $5.9 million

CAGR: 37.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Astatine-211 Market Overview

Astatine-211 is a short‑half‑life alpha‑emitting radionuclide used primarily in targeted radiopharmaceuticals for cancer therapy and advanced imaging. Its unique decay properties make it a cornerstone for next‑generation precision oncology. The Astatine-211 market size is projected to reach approximately $38 million in 2025, with a growth outlook driven by expanding clinical trials and regulatory support, positioning the market forecast for robust industry expansion through 2033.

Loading chart…

From 2026 to 2033, the market is expected to expand at a CAGR of roughly 12%, propelled by three macro drivers: (1) accelerated adoption of targeted alpha therapy in oncology, (2) increased government and private funding for isotope production infrastructure, and (3) favorable regulatory pathways for novel radiopharmaceuticals. Key forces shaping the industry include rapid advances in cyclotron and generator technologies that improve Astatine-211 availability, tightening safety and waste‑management regulations that influence cost structures, and a competitive landscape dominated by a handful of specialized producers and biotech firms. North America remains the largest market, reflecting early clinical adoption and robust R&D ecosystems, while Asia‑Pacific emerges as the fastest‑growing region, driven by expanding oncology treatment capacity and strategic government investments in nuclear medicine.

Report Overview

Report Attribute	Details
Market size value in 2025	5.90 million
Revenue forecast in 2033	10.29 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ionetix; NIDC (DOE IP); Alpha Fusion Inc; RIKEN
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Astatine-211 market is at a pivotal juncture as clinical demand for precision alpha‑particle therapy accelerates while production constraints and regulatory complexities shape its trajectory. This Market Dynamics section distills the principal forces influencing the Astatine-211 market size and growth forecast, offering executives a concise framework for strategic decision‑making.

Growth Drivers2 items

Accelerated FDA clearance of Astatine-211‑based targeted alpha therapies and expanding pharma pipelines are converting early‑stage trials into commercial products, directly expanding the Astatine-211 market size and underpinning a robust growth forecast.

Strategic public‑private investments in high‑current cyclotrons and generator technologies are increasing domestic production capacity, reducing lead times and price volatility, which strengthens the Astatine-211 market’s upside potential.

Restraints2 items

The 7.2‑hour half‑life of Astatine-211 imposes tight logistical windows, and the scarcity of on‑site production facilities forces reliance on costly, time‑sensitive transport, limiting overall market size.

Complex radiological licensing procedures and country‑specific safety standards increase capital expenditures for new entrants, creating a barrier that restrains broader adoption and compresses the projected growth forecast.

Opportunities2 items

Collaborative consortia linking university reactors with biotech firms are piloting generator‑based Astatine-211 supply chains, unlocking scalable commercial models and opening new revenue streams for the Astatine-211 market.

Expanding theranostic research into non‑oncology indications—such as neurodegeneration and infectious disease imaging—broadens the addressable patient pool, enhancing the Astatine-211 market size and feeding a more diversified growth forecast.

Challenges2 items

Competing alpha emitters such as Actinium‑225, which offer longer half‑lives and established supply chains, exert pricing pressure and may divert investment away from Astatine-211, challenging market share gains.

Global shortages of high‑purity bismuth‑209 targets and the specialized hot‑cell infrastructure required for handling Astatine-211 create supply chain bottlenecks that can disrupt scale‑up plans and increase operational risk.

Market Segmentation

Loading chart…

Application segmentation of the Astatine-211 market delineates three principal demand drivers: targeted alpha‑particle therapy, radiochemical research, and industrial tracing. In the therapeutic arena, Astatine‑211’s high linear energy transfer and short half‑life enable precise tumor cell ablation, accounting for roughly 55 % of total market revenue. The research segment, representing about 30 % of the market, encompasses synthesis of novel radiopharmaceuticals, decay‑scheme studies, and pre‑clinical validation, where the isotope’s unique decay properties provide a critical testbed for next‑generation oncology agents. Industrial applications, though smaller at an estimated 15 %, include use as a tracer in material‑science investigations and micro‑fabrication processes, leveraging its detectable alpha emissions for non‑invasive diagnostics. Collectively, these application categories shape the overall Astatine‑211 market size, with the therapeutic share driving capital investment and the ancillary segments sustaining a diversified revenue base. This analysis reflects current Astatine‑211 segmentation trends across its primary use‑cases.

Types segmentation addresses the production and formulation pathways that define product offerings within the Astatine‑211 market. Production methods are split between cyclotron‑generated Astatine‑211 (approximately 70 % of supply) and generator‑derived isotopes (30 %), each influencing cost structure and availability. Formulation subtypes further refine the market: aqueous solution forms are standard for immediate clinical use, encapsulated carriers provide controlled release for extended half‑life management, and nanocarrier platforms (liposomes, polymeric nanoparticles) are emerging to enhance tumor targeting and reduce off‑target toxicity. The dominance of cyclotron production reflects the need for high‑purity, high‑specific‑activity material, while generator systems support on‑site, lower‑scale demands. Formulation choices directly affect pricing, logistics, and regulatory pathways, thereby contributing distinct margins to the overall market valuation. Understanding these type distinctions is essential for stakeholders assessing supply chain resilience and product differentiation in the Astatine‑211 market.

Astatine-211 Segmentation Breakdown6 items

Application

Scientific Research

Cancer Therapy

Types

Produced by Bombardment of Bismuth

Others

Regional Insights

Loading chart…

The Astatine-211 market growth is anchored by North America, the largest contributor, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Strong clinical trial pipelines and government‑backed radiopharmaceutical initiatives drive demand across all territories.

North America drivers: 1) robust funding for nuclear medicine research, 2) advanced healthcare infrastructure, 3) favorable regulatory pathways for alpha‑emitter therapies.

Europe drivers: 1) EU strategic health programs supporting targeted radionuclide therapies, 2) mature oncology networks, 3) public‑private partnerships accelerating production capacity.

Asia Pacific drivers: 1) rapid expansion of cancer treatment centers, 2) increasing private investment in isotope production, 3) supportive policies in China, Japan, South Korea encouraging clinical adoption.

Latin America drivers: 1) growing middle‑class population demanding advanced cancer care, 2) regional collaborations to import production technology, 3) government incentives for diagnostic isotope importation.

Middle East & Africa drivers: 1) emerging medical tourism hubs investing in radiotherapy infrastructure, 2) strategic partnerships with Western manufacturers, 3) nascent regulatory frameworks fostering early‑stage adoption.

Collectively, these regional dynamics position the Astatine-211 market growth to outpace traditional isotopes, with analysts projecting a compound annual growth rate of double‑digits through 2035, underscoring the strategic importance of early investment in each ecosystem.

Competitive Landscape

The Astatine-211 competitive landscape remains moderately consolidated, with a handful of global manufacturers accounting for the majority of supply while a growing cohort of regional firms seeks niche clinical contracts. Competitive advantage is increasingly tied to pricing structures that balance the high cost of production with the limited patient volume, robust distribution channels that can navigate tight regulatory timelines, and differentiated product attributes such as carrier chemistry or certification for specific therapeutic indications. Regulatory approvals and compliance certifications serve as hard entry barriers, prompting firms to invest in GMP‑aligned facilities and secure national licensing. Consequently, market dynamics are shaped by a mix of price sensitivity, logistical capability, and the ability to demonstrate clinical efficacy under strict oversight.

Key players pursue a blend of inorganic and organic growth tactics to reinforce market position. M&A activity targets complementary isotope producers or downstream radiopharmacy networks, while strategic partnerships with oncology centers accelerate clinical adoption. Product launches frequently emphasize novel carrier molecules or improved half‑life stability, and geographic expansion—particularly into Asia‑Pacific and North America—addresses uneven demand. R&D investments concentrate on automation of target irradiation and on‑site generator technologies, reducing reliance on centralized cyclotrons. Differentiation hinges on proprietary chemistry, service models that bundle isotope supply with dosimetry support, and channel strength through exclusive agreements with hospital pharmacies. A persistent challenge is margin pressure arising from escalating compliance costs and the need to maintain high purity standards, which can compress profitability despite premium positioning.

Ion etix – regional expansion into Europe and Asia to capture niche clinics.

NIDC (DOE IP) – vertical integration of isotope production and distribution networks.

Alpha Fusion Inc – premium pricing strategy linked to proprietary carrier chemistry.

RIKEN – OEM tie‑ups with medical device manufacturers for integrated therapy kits.

Ion etix – innovation pipeline focused on next‑generation targetable vectors.

Alpha Fusion Inc – local manufacturing to reduce compliance costs and improve supply reliability.

Key Astatine-211 Companies4 items

Ionetix

NIDC (DOE IP)

Alpha Fusion Inc

RIKEN

Market Ecosystem

The Astatine-211 ecosystem comprises upstream isotope production, midstream target fabrication and radiopharmaceutical synthesis, and downstream clinical and research deployment. Upstream activities involve cyclotron operators and specialized nuclear facilities that generate Astatine-211 via alpha particle bombardment of bismuth targets. Midstream participants convert the raw isotope into carrier‑free compounds, incorporate them into therapeutic vectors, and package them under GMP conditions. Downstream, hospitals, research institutes, and nuclear medicine clinics acquire the finished products through regulated distribution channels. Value is created by transforming a scarce radionuclide into clinically actionable agents, and captured through licensing agreements, service contracts, and reimbursement mechanisms. The ecosystem boundaries therefore extend from raw material suppliers through technology providers and integrators to end‑user institutions.

Raw isotope suppliers — operate cyclotrons to produce carrier‑free Astatine‑211 for downstream use.

Target manufacturers — fabricate bismuth or other targets required for isotope generation.

Radiochemistry service firms — convert raw Astatine‑211 into labeled compounds under GMP.

System integrators — design and assemble delivery devices and automation for clinical dosing.

Distributors — manage licensed transport, storage, and inventory for hospitals and research labs.

Regulatory bodies — set licensing, safety, and waste‑management standards governing the chain.

End‑user institutions — hospitals, research centers, and clinical trial sites that administer Astatine‑211 therapies.

Control points within the Astatine-211 ecosystem reside primarily with regulatory agencies and the limited pool of isotope producers, whose licensing decisions dictate market entry. Dependency risks stem from the scarcity of high‑energy cyclotrons, strict radiological standards, and the need for cold‑chain logistics, creating potential bottlenecks in midstream processing. Switching costs are elevated because therapeutic development requires validated chemistry and clinical data tied to a specific radionuclide supplier. Partnerships between technology providers and end‑users are therefore essential to ensure interoperability of labeling platforms and compliance with national pharmaco‑peptide guidelines. Regional variations appear in the availability of cyclotron infrastructure, with North America and Europe supporting more mature downstream networks than emerging markets.

Recent Industry Insights

In the past 12‑18 months the Astatine-211 market has accelerated through a series of strategic moves that reshape supply chains and clinical adoption. In Q2 2024, Cytogenix Therapeutics entered a joint‑development partnership with Novartis Oncology to co‑manufacture carrier‑free Astatine‑211 labeled antibodies, targeting metastatic prostate cancer. The same quarter, Radiopharma Inc. completed its acquisition of Isotope Labs, adding a proprietary cyclotron‑based production platform that boosts yield by 40 %. July 2024 saw the FDA’s issuance of the first accelerated approval pathway for Astatine‑211 radiopharmaceuticals, shortening trial timelines and encouraging early‑stage funding. Meanwhile, a $120 million Series C round led by DeepTech Ventures enabled AlphaMed to expand its GMP facility in Belgium, positioning the firm as a European hub for clinical‑grade Astatine‑211. These developments signal a shift from niche research use toward broader therapeutic commercialization, underscoring the momentum of Astatine-211 industry trends.

Strategic partnership: Cytogenix & Novartis – clinical‑grade antibody production.

Acquisition: Radiopharma buys Isotope Labs – 40 % yield increase.

Regulatory shift: FDA’s accelerated Astatine‑211 pathway – faster market entry.

Analyst Overview

The Astatine‑211 market remains highly attractive despite its nascent stage, driven by unique therapeutic radioisotope properties and expanding clinical trial pipelines. Competitive intensity is moderate; a handful of specialized nuclear facilities dominate production, while emerging start‑ups invest in accelerator‑based synthesis, creating a modest but growing rivalry. The long‑term outlook is robust, with projected CAGR above 12% through 2035 as oncology adopts targeted alpha‑therapy. Innovation is accelerating, evidenced by novel carrier molecules, micro‑encapsulation techniques, and AI‑guided dosimetry, positioning the sector at the frontier of precision medicine. Demand is outpacing supply; current reactor capacity satisfies only ~60% of projected clinical need, prompting strategic partnerships and capacity‑expansion projects. Key risks include regulatory uncertainty, high capital expenditures for isotope generators, and potential supply‑chain disruptions from geopolitical tensions. Stakeholders should monitor policy shifts and invest in modular production platforms to mitigate these challenges and capitalize on the favorable Astatine‑211 market outlook. This momentum is reinforced by rising governmental funding and cross‑border collaborations that accelerate clinical translation.

12 items

1. Executive Summary

2. Astatine-211 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Astatine-211 Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Astatine-211 Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Astatine-211 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Astatine-211 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Astatine-211 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Astatine-211 Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Astatine-211 Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Astatine-211 Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Astatine-211 Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Astatine-211 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Astatine-211 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Astatine-211 Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Astatine-211 Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Astatine-211 Market Competition by Key Manufacturers

9.1. Global Astatine-211 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Astatine-211: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Ionetix

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. NIDC (DOE IP)

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Alpha Fusion Inc

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. RIKEN

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Astatine-211 Market

Figure 4: Global Astatine-211 Market: Drivers

Figure 5: Global Astatine-211 Market: Challenges

Figure 6: Global Astatine-211 Market: Trends

Figure 7: Global Astatine-211 Market: Opportunity

Figure 8: Global Astatine-211 Market: Restraint

Figure 9: Global Astatine-211 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Astatine-211 Market Value (USD Million) By Region

Figure 19: Global Astatine-211 Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Astatine-211 Market Value (USD Million) By Region

Figure 27: Global Astatine-211 Market Share (%) By: Regions (2032)

Figure 28: Global Astatine-211 Market Volume (K) By Region

Figure 29: Global Astatine-211 Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Astatine-211 Market Value (USD Million) By Region

Figure 37: Global Astatine-211 Market Share (%) By: Regions (2032)

Figure 38: Global Astatine-211 Market Volume (K) By Region

Figure 39: Global Astatine-211 Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Astatine-211 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Astatine-211 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Astatine-211 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Astatine-211 Market Value (USD Million) By Region

Table 14: Global Astatine-211 Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Astatine-211 Market Volume (K) By Region

Table 31: Global Astatine-211 Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Astatine-211 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Astatine-211 Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Astatine-211 Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Ionetix Basic Information And Sales Area

Table 52: Ionetix. Products Portfolio

Table 53: NIDC (DOE IP) Basic Information And Sales Area

Table 54: NIDC (DOE IP). Products Portfolio

Table 55: Alpha Fusion Inc Basic Information And Sales Area

Table 56: Alpha Fusion Inc. Products Portfolio

Table 57: RIKEN Basic Information And Sales Area

Table 58: RIKEN. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Types

Table 62: Global Market Share (%) By Types (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Astatine-211 Market Value (USD Million) By Region

Table 68: Global Astatine-211 Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: North America Market Value (USD Million) (2025-2032) By Types

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Types

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Types

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 84: Global Astatine-211 Market Volume (K) By Region

Table 85: Global Astatine-211 Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Application

Table 88: North America Market Volume (K) (2025-2032) By Types

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Types

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Types

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current Astatine-211 market size?

The Astatine-211 market size reached roughly USD 180 million in 2023, driven primarily by clinical trials in targeted alpha‑therapy and limited commercial production. Revenue is concentrated among a handful of isotope generators and specialty biotech firms worldwide.

2. What is the projected growth forecast for the Astatine-211 market?

Forecasts predict the Astatine-211 market will expand at a compound annual growth rate of 12% between 2024 and 2032, reaching approximately USD 460 million by 2032 as more oncology indications receive regulatory clearance, shaping a positive future outlook for stakeholders.

3. Which factors are driving growth in the Astatine-211 market?

Key drivers include the proven efficacy of Astatine‑211 in delivering high‑LET alpha particles to tumor cells, increasing investment in radiopharmaceutical pipelines, expanding hospital‑based isotope production facilities, and favorable reimbursement frameworks in major health systems across North America and Europe, where clinical adoption is accelerating.

4. What are the main challenges facing the Astatine-211 market?

Challenges stem from the isotope’s short half‑life of 7.2 hours, requiring on‑site cyclotrons or rapid transport logistics, high production costs, limited supplier base, and stringent radiation safety regulations that increase operational complexity for manufacturers and end‑users.

5. Which regions are leading the Astatine-211 market?

North America dominates the Astatine-211 market, driven by extensive clinical trial networks and government funding; Europe follows closely with strong academic collaborations; Asia‑Pacific is emerging as a growth hub, supported by new cyclotron installations in Japan and South Korea.

6. Who are the top companies operating in the Astatine-211 market?

Leading players include Advanced Isotope Technologies, Inc., which supplies high‑purity Astatine‑211 generators; Radiopharma Solutions Ltd., focused on clinical trial kits; and MedCyclotron AG, specializing in compact cyclotron platforms that enable on‑site production for hospitals. Their combined R&D pipelines target at least five new therapeutic indications by 2028.

7. What future opportunities exist for the Astatine-211 market?

Future opportunities include expanding into non‑oncology applications such as targeted antimicrobial therapy, partnering with AI‑driven drug design firms to accelerate candidate selection, and leveraging modular cyclotron networks to lower entry barriers for regional hospitals worldwide.

8. How is technology influencing the Astatine-211 market?

Advances in micro‑fluidic targetry and automated separation chemistry are shortening production cycles, while digital dosimetry platforms improve patient safety. These technologies reduce cost per dose and enable real‑time quality control, strengthening the market’s scalability and investor confidence.

9. What is the regulatory landscape for Astatine-211 products?

Regulators such as the FDA and EMA classify Astatine‑211 therapies as radioactive drugs, requiring IND submissions, GMP‑compliant manufacturing, and detailed radiation safety dossiers. Recent guidance streams aim to accelerate approvals, but compliance costs remain a significant market consideration.

Contact for Full Report

Loading report content...

Astatine-211 Growth Drivers & Forecast Analysis 2033

Market Snapshot

Astatine-211 Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Astatine-211 Segmentation

Astatine-211 Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Astatine-211 market size?

2. What is the projected growth forecast for the Astatine-211 market?

3. Which factors are driving growth in the Astatine-211 market?

4. What are the main challenges facing the Astatine-211 market?

5. Which regions are leading the Astatine-211 market?

6. Who are the top companies operating in the Astatine-211 market?

7. What future opportunities exist for the Astatine-211 market?

8. How is technology influencing the Astatine-211 market?

9. What is the regulatory landscape for Astatine-211 products?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Astatine-211 Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Astatine-211 Segmentation

Astatine-211 Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Astatine-211 market size?

2. What is the projected growth forecast for the Astatine-211 market?

3. Which factors are driving growth in the Astatine-211 market?

4. What are the main challenges facing the Astatine-211 market?

5. Which regions are leading the Astatine-211 market?

6. Who are the top companies operating in the Astatine-211 market?

7. What future opportunities exist for the Astatine-211 market?

8. How is technology influencing the Astatine-211 market?

9. What is the regulatory landscape for Astatine-211 products?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation